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Abstract
Background: A small number of studies have shown that the use of cannabis increases the risk of bronchial
asthma. There is, however, a paucity of longitudinal studies which are able to control for known risk factors of
bronchial asthma.
Methods: Survey data from a population-based longitudinal study encompassing 2602 young adults followed for
13 years were coupled with individual prescription data on asthma medication (β2-adrenergic receptor agonists
and glucocorticoids for inhalation) from the Norwegian national prescription database, which covers the entire
Norwegian population. Current cannabis use, gender, age, years of education, body mass index (BMI; kg/m2) and
current smoking were measured.
Results: Prescription of asthma medication was associated with female gender, self-reported earlier asthma and
allergies, daily tobacco smoking and current cannabis use. In a model adjusting for gender, age, years of education,
BMI, earlier self-reported asthma and allergies and current tobacco smoking the odds ratio for a current cannabis
user to fill prescriptions for asthma medication was 1.71 (95% CI: 1.06–2.77; p = 0.028).
Conclusions: This suggests that cannabis is a risk factor for bronchial asthma or use of asthma medication even
when known risk factors are taken into consideration. Intake of cannabis through smoking should be avoided in
persons at risk.
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Background
Bronchial asthma is a common long-term inflamma-
tory disease of the airways characterized by variable
and recurring symptoms, reversible airflow obstruc-
tion, and bronchospasm. Symptoms include episodes
of wheezing, coughing, chest tightness and shortness
of breath and are often symptomatically diagnosed
and treated with broncho-dilatators and/or steroids
for inhalation.
Known risk factors for bronchial asthma are family
history of asthma, allergies, respiratory infections [1],
environmental pollutions (including dust mite [2] and
air pollution [3]), tobacco smoking [4] and obesity
[5]. Some studies also find female gender to be a risk
factor [6].
The recent changes in attitude towards cannabis use,
where the drug is perceived as almost harmless [7], and
recent changes in legislation regulating its use, especially
in the US, may increase the risk of asthma from
increased cannabis use [8]. Greater awareness of the
possible negative consequences of cannabis use would
be prudent. Since cannabis, despite the development
of novel ways of use, is most often smoked as
marijuana by itself or as hashish together with
tobacco, there is concern that its use might inflict
respiratory consequences [9].
Cannabis users seem to have an increased risk of
chronic bronchitis [10], reporting signs like coughing,
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sputum and wheezing, but no more shortness of breath
[11–13]. A feared long-term negative consequence of
chronic bronchitis is chronic obstructive pulmonary
disorder (COPD) [14], but current research suggests
that the use of cannabis does not increase the risk of
COPD [15, 16].
Another consequence of cannabis smoking could be
bronchial asthma. Three lines of research have been
followed in this context. Firstly, some studies have inves-
tigated the potential acute bronchodilator effects of can-
nabis. Several older studies have shown a significant
positive airway effect on bronchial asthma of cannabis
administered in different ways to both healthy volunteers
and asthmatic patients [10, 17–21]. Secondly, some cases
have been observed where allergy to some components
of cannabis seems to precipitate asthma [22, 23].
Thirdly, several larger population studies found an in-
crease in symptoms of bronchial asthma in cannabis
users: Several US cross-sectional health surveys have
found more bronchial asthma among users of cannabis
compared to others, even after controlling for age,
gender, and tobacco use [13, 16, 24]. Moreover, three
publications from the longitudinal Dunedin birth cohort
study initially found an effect on asthma among all
cannabis users, but when controlling for several
confounders only found the association in women [25].
Results from the study also showed a positive effect on
asthma from quitting cannabis [26]. Most population stud-
ies control for gender and tobacco use [13, 16, 24–27],
some by analysing the effect only in non-users of tobacco
[24]. Some even control for previous asthma [16, 25, 27],
but few if any control for being overweight or for the
presence of allergies. Overall the studies together
suggest that there is an association of cannabis with
bronchial asthma [28], with an overall effect a little
less than for tobacco smokers [13]. Still, there are a
limited number of studies investigating the relation-
ship between cannabis use and bronchial asthma
while controlling for a variety of potential covariates,
and further studies are therefore needed [9]. We have
found no studies with the prescriptions for asthma
medication as outcome measure.
In Norway cannabis is mostly consumed as hashish,
the resin of cannabis, prepared and mixed with tobacco
and inhaled in cigarettes or joints. It is therefore import-
ant to control for tobacco smoking when investigating
the possible effects of cannabis on the use of drugs for
bronchial asthma.
In this longitudinal study we investigated the relation-
ship between self-reported cannabis use and future
filling of prescriptions for inhaled bronchodilators or
steroids for the treatment of bronchial asthma, taking




This study is based on data from the Young in Norway
Study, described in more detail elsewhere [29, 30]. A
population-based sample of Norwegian adolescents was
followed over a 13-year span with four data collections.
The initial sample at the first time point (T1) was com-
posed of 12,287 persons with a response rate of 97%.
Only parts of the sample was invited for follow-up at
later time points, and the cumulative response rate over
all four data collection times for those who were eligible
to be included at all data collection points was 69%.
Participants were asked to give their consent to obtain
information about them in various nationwide official
registers such as the Norwegian Prescription Database
(NorPD), and 90.0% consented to such linkage. In this
study, we drew on the available data from 2602 individ-
uals, 1145 males (44.0%) and 1457 females (56.0%).
Survey data were collected at four times and mean age
of the respondents at these data collection points was
T1: 15.05 (SD = 1.96 in 1992), T2: 16.53 (1994), T3: 22.95
(1999) and T4: 28.48 years (2005–6), respectively.
Questionnaire data from the Young in Norway Study
were linked to register data from the NorPD. Since 1
January 2004, all pharmacies in Norway are obliged, by
law, to submit monthly electronic data on dispensed
prescriptions to the Norwegian Institute of Public
Health. The NorPD contains information on all
prescription drugs, reimbursed or not, dispensed at
Norwegian pharmacies to individual patients who live
outside institutions [31]. The register contains informa-
tion about all prescriptions, including the patients’
unique identifiers (encrypted), gender, age, date of dis-
pensing and drug information, including brand name
and anatomical therapeutic chemical (ATC) code [32].
The data from the Young in Norway Study and NorPD
were linked by Statistics Norway as a third party ensur-
ing the anonymity of the responders. The survey data
from Young in Norway Study or NorPD were not visible
for Statistics Norway during the linkage prosess.
Measures
Cannabis use parameters were taken from the Young in
Norway Study. Cannabis use was measured at T4. We
categorized respondents into three groups according to
their self-reported use of cannabis: those who had never
used cannabis; those who had used cannabis at least
once in their lifetime, but not in the last 12 months; and
those who had used cannabis at least once during the
last 12 months.
Gender, age, years of education and body mass index
(BMI; kg/m2) were taken from reports at T4, while
self-reported information on asthma (“Do you have
asthma?” no/yes) and allergies (“Are you bothered by
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allergies?” no/yes) were taken from the earlier data
collection at T1. Information on tobacco smoking habits
were taken from T4, categorizing the responders into:
those who had never smoked regularly; those who
smoked regularly before, but not now; those who
currently smoked sometimes, but not daily; and current
daily smokers.
Information about all anti-asthma medication pre-
scriptions between 2007 and 2015 were obtained
through the NorPD, and we compared participants who
did not obtain any prescriptions for these drugs in this
time interval with participants who did. The interval be-
tween self-reported cannabis use and filling a prescrip-
tion could thus vary from 1 to 9 years. The drugs
studied were β2-adrenergic receptor agonists (ATC code
R03A*) and glucocorticoids for inhalation (R03B*).
Statistical analysis
Bivariate relationships between the explanatory
variables and the outcome variable “prescriptions for
anti-asthmatic drugs” were examined using chi square
tests for categorical variables and Student’s T-tests for
continuous variables. We also examined how our
main explanatory variable “cannabis use” was related
to other explanatory variables by using chi square for
categorical variables and ANOVA for continuous vari-
ables. In a new set of analyses we performed binary
logistic regressions with anti-asthmatic drug prescrip-
tions as outcome, presenting firstly unadjusted odds
ratios (OR) with 95% confidence intervals (95% CI),
then a model adjusting for gender, age, earlier
self-reported asthma and allergies, and a final model
adjusting additionally for level of education, BMI and
smoking habits. P-values of less than 0.05 were
considered statistically significant, but mostly exact
p-values are presented.
Results
Women were prescribed anti-asthmatic drugs more
often than men (p < 0.001), but there seemed to be no
effect of age, years of education or BMI (Table 1).
Those who reported at T1 to be bothered with asthma
(p < 0.001) and allergies (p = 0.005) more often filled pre-
scriptions for anti-ansthmatic drugs. Daily current tobacco
smokers also filled prescriptions more often (p = 0.007), as
did current users of cannabis (p = 0.009).
Current users of cannabis were more often men
(p < 0.001) and of young age (p < 0.001) (Table 2).
Years of education was not related to use of cannabis, but
BMI tended to be somewhat lower amongst cannabis
users (p = 0.059). Neither self-reported asthma nor aller-
gies at T1 were related to cannabis use, but current
tobacco smokers, both daily and occasional, more often
reported being current cannabis users (p < 0.001).
In binary logistic regressions with filling prescriptions
for anti-asthmatic drugs as outcome, female gender, re-
ported asthma and allergies at T1, current daily smoking,
and cannabis use last year were all significantly associ-
ated with filling a prescription for asthma medications
(Table 3, Unadjusted Model). In a model adjusting for
gender, age, self-reported asthma and allergies at
T1(Table 3, Model 1), results showed that females had
a two-fold increased odds of filling such a prescrip-
tion (p < 0.001), those with self-reported asthma at T1
had a 2.5 times increased odds of filling such a
prescription (p < 0.001) and those currently using
cannabis had a 2.1 times increased odds of filling a
prescription for asthma medications (p = 0.028). In a
model additionally adjusting for level of education,
BMI and smoking habits (Table 3, Model 2), approxi-
mately the same values were found, other than
self-reported allergies at T1 which emerged to be
significantly associated with filling prescriptions for
anti-asthmatic drugs (p = 0.025). We found no signifi-
cant relationship between current daily smoking and
filling prescriptions for anti-asthmatic drugs (OR 1.20;
95% CI: 0.78–1.85). The OR for filling a prescription
for asthma medication among recent users of canna-
bis was 1.71 (95% CI: 1.06–2.77) in this final model.
We also performed a binary logistic regression stratify-
ing the material according current daily smoking (those
currently smoking daily and all others analyzed
separately). This analysis did not change the outcome of
the binary logistic regression substantially, even though
the association between cannabis use and prescription of
asthma medication did not reach significance among the
current daily smokers (p > 0.05; data not shown in the
table), probably because to the size of the group of
current smokers was too small (N = 457).
Discussion
This study combined survey data and data from a
national prescription registry to demonstrate that the
filling of presciptions for asthma medications was related
to current, but not former, cannabis use. The odds for
filling a prescription increased two-fold for current
cannabis users compared to those who had never used
cannabis and this increased odds withstood adjustment
for all other relevant risk factors, such as female gender,
self-reported asthma and allergies in adolescence, and
even daily smoking in a comprehensive regression
model.
The use, in our study, of prescription of asthma
medication as outcome measure is novel, but our finding
is in line with several studies indicating a negative effect
of cannabis use on respiratory function and the precipi-
tation of asthma [13, 16, 24–27]. We found an increase
of approximately 70% in the prescription of asthma
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medication among cannabis users. This increase is com-
parable to other studies which have found similar levels
of increased risk [13, 16, 26, 27].
The validity of the study design and the findings was
strengthened by fact that the study identified that partic-
ipants’ self-report of having asthma at an earlier time
point was, in itself, a risk factor for filling a prescription
for asthma medications. Study findings are also in
accordance with previous studies by showing thatpre-
viously identified risk factors such as female gender [6],
tobacco smoking [4] and at a trend level BMI [5] in-
creased the odds of asthma medication being prescriped.
Controlling for these factors only marginally changed
the relationship between cannabis use and filling a pre-
scription for asthma medication. We cannot ultimately
rule out the possibility of residual confounding. We
were, however, able to control for having allergies, a
known risk factor for asthma [1], but this still did not
change the impact of current cannabis use on asthma.
We have found no other studies investigating the rela-
tionship beween cannabis use and asthma medication
that have been able to adjust for self-reported allergies.
Our study also indicated no effect of former (but not
current) cannabis use on asthma medication prescription.
Former use could indicate people who have only tried
cannabis, an exposure less likely to have negative health
effects. As we lack measures on the amount of cannabis
used, this finding should be interpreted cautiously, but it
may be in line with earlier suggestions that quitting canna-
bis is beneficial for lung function and reduces asthma
symptoms [26].
Our study cannot completely rule out the possibility of
reversed causality, i.e. that patients with asthma use can-
nabis to relieve symptoms. Some studies do show that
cannabis may relieve symptoms of airway obstruction
and asthma [10, 17–21]. However, our results show that
asthma in adolescent years (at T1) was not related to
cannabis use. Moreover, we did adjust for asthma at an
earlier time point in our study. It is still possible that
people are using cannabis to alleviate asthma symptoms,
without a formal diagnosis of asthma or awareness of
having the condition.
The study had a sufficiently large cohort of young
adults with enough exposure to cannabis in order to
detect potential negative effects of cannabis use. The
national coverage of NorPD ensured complete data for
prescriptions filled. We do not know, however, if
prescribed drugs were in fact used, as we have no
Table 1 Distribution of predictor variables according to having filled prescriptions for anti-asthma medication between 2007 and 2015
No prescriptions At least one prescription Difference test Test statistics/p-value
Gender
Men N (%) 1076 94.0 69 6.0
Women N (%) 1307 89.7 150 10.3 15.16 <.001
Age Mean (SD) 28.49 1.96 28.41 2.21 0.60 .551
Education (in years) Mean (SD) 14.96 2.17 14.88 2.11 0.50 .615
Body mass index Mean (SD) 24.36 4.04 24.60 4.34 0.80 .423
Asthma at T1
No asthma N (%) 2155 92.3 179 7.7
Asthma N (%) 125 82.2 27 17.8 19.13 <.001
Allergies at T1
No allergies N (%) 1817 92.5 147 7.5
Allergies N (%) 463 88.7 59 11.3 7.91 .005
Smoking at T4
Has never smoked N (%) 1315 92.9 100 7.1
Smoked daily before, but not now N (%) 340 89.9 38 10.1
Smokes sometimes, but not daily N (%) 261 92.9 20 7.1
Smokes daily N (%) 457 88.4 60 11.6 12.10 .007
Cannabis use at T4
Never used cannabis N (%) 1569 92.0 137 8.0
Has use cannabis before, but not last year N (%) 483 93.2 35 6.8
Used cannabis last year N (%) 277 87.4 40 12.6 9.50 .009
at-values for continous variables; χ2-values for categorical variables
Outcome measures are register data from the Norwegian Prescription Database and explanatory variables are taken from the longitudinal Young in Norway Study
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information of secondary non-compliance. Furthermore,
filling a prescription for asthma medication is not the
same as a diagnosis of asthma. A prescription is only a
proxy for the disease. Investigations show that asthma
may be undertreated [33], and this may lead to an
under-estimation of a diagnosis of asthma. We have no
information regarding whether such under-treatment
should be more or less severe among cannabis users,
and do not know if this has introduced a bias. Further-
more, the responders were followed for a sufficient time
to pick up on negative health effects, as we followed the
respondents’ prescription records up to 9 years after the
Table 3 Logistic regression results with prescriptions of anti-asthma medication as outcome
Reference (OR = 1) Unadjusted Model 1 Model 2
OR 95% CI p OR 95% CI p OR 95% CI p
Female gender Male 1.79 1.22–2.41 < 0.001 2.00 1.45–2.75 < 0.001 2.15 1.51–3.05 < 0.001
Age Continuous 0.98 0.91–1.05 0.551 0.98 0.91–1.05 0.547 0.96 0.89–1.05 0.370
Education Continuous 0.98 0.92–1.05 0.615 0.97 0.90–1.05 0.442
Body mass index Continuous 1.01 0.98–1.05 0.423 1.04 1.00–1.08 0.050
Asthma at T1 No asthma 2.60 1.67–4.05 < 0.001 2.48 1.52–4.03 < 0.001 2.49 1.50–4.13 < 0.001
Allergies at T1 No allergies 1.58 1.15–2.17 0.005 1.38 0.98–1.95 0.067 1.51 1.05–2.17 0.025
Smoking at T4 Never smoked
Smoked daily before, but not now 1.47 0.99–2.18 0.054 1.15 0.73–1.83 0.540
Smokes sometimes, but not daily 1.01 0.61–1.66 0.976 0.88 0.51–1.56 0.678
Smokes daily 1.73 1.23–2.42 0.002 1.20 0.78–1.85 0.414
Cannabis use at T4 Never used cannabis
Used cannabis before, but not last year 0.83 0.57–1.22 0.342 0.85 0.57–1.27 0.423 0.82 0.53–1.28 0.378
Used cannabis last year 1.65 1.14–2.41 0.009 2.05 1.38–3.05 < 0.001 1.71 1.06–2.77 0.028
Note: OR = odds ratio; 95% CI = 95% confidence interval of OR
Data on prescriptions are taken from the Norwegian Prescription Database and and explanatory variables are taken from the longitudinal Young in Norway Study.
Model 1 includes adjustment for gender, age, self-reported asthma or allergies in addition to cannabis smoking. Model 2 includes additional adjustment for
education, BMI and smoking
Table 2 Distribution of predictor variables according to use of cannabis at T4
Never used cannabis Has used cannabis before,






Men N (%) 682 60.7 247 22.0 194 17.3
Women N (%) 1024 72.2 271 19.1 123 8.7 52.03 < 0.001
Age Mean (SD) 28.56 2.01 28.46 1.88 28.07 1.91 8.34 < 0.001
Education (in years) Mean (SD) 14.92 2.14 15.03 2.20 15.05 2.26 0.75 0.471
Body mass index Mean (SD) 24.49 4.06 24.33 4.18 23.90 3.70 2.83 0.059
Asthma at T1
No asthma N (%) 1530 67.0 462 20.2 292 12.8
Asthma N (%) 100 69.0 33 22.8 12 8.3 2.72 0.256
Allergies at T1
No allergies N (%) 1290 67.4 394 20.6 231 12.1
Allergies N (%) 340 66.1 101 19.6 73 14.2 1.74 0.419
Smoking at T4
Has never smoked N (%) 1132 81.9 175 12.7 75 5.4
Smoked daily before, but not now N (%) 208 56.4 121 32.8 40 10.8
Smokes sometimes, but not daily N (%) 135 48.4 72 25.8 72 25.8
Smokes daily N (%) 226 45.0 147 29.3 129 25.7 360.28 < 0.001
aF-values for continous variables; χ2-values for categorical variables
All data taken form the longitudinal Young in Norway Study
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last questionnaire. However, the study is limited by not
providing information about how much cannabis partici-
pants had used or if they were using cannabis in the
whole time period.
Conclusions
The study strengthens earlier findings and suggests that
current use of cannabis is a risk factor for precipitating
asthma, even when other known risk factors for asthma
are taken in to consideration. No previous studies have
used asthma medication as an outcome. These findings
are important in the light of the changes in legislation
being considered in many countries. Those who opt
taking cannabis may need to find alternatives to smoking
it. The ongoing measurement of respiratory function
amongst cannabis users is advisable.
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